Just before the New Year, the US Food and Drug Administration (FDA) awarded national priority vouchers for two investigational drugs for their “potential to increase access through affordability for American patients.”
The products are Merck’s enlicitide decanoate, an oral PCSK9 inhibitor for lowering LDL cholesterol, and Sacituzumab tirumotecan, an antibody-drug